Most of the digital health experts we spoke to for this issue of Deep Dive made one thing clear – no one can really say what the future holds for digital tech in the pharma and healthcare i
Analysts casting their eyes forward to 2022 see big pharma maintaining its position in the sector, protected by vast war chests and ready to pounce on any newcomer that shows promise.
"One of the biggest challenges is how to access data that’s within the hospitals and building links to other data sources to get the data needed for effective research," says Shahid Hanif
Biogen has scaled back its ambitions for Denali-partnered Parkinson’s disease candidate BIIB122, abandoning a complex and likely costly phase 3 trial that isn’t due to com
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas